Enterprise Value
51.39M
Cash
1.553M
Avg Qtr Burn
-7.977M
Short % of Float
2.69%
Insider Ownership
13.78%
Institutional Own.
29.91%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OLPRUVA™ (ACER-001) Details Urea cycle disorder | Approved Quarterly sales | |
EDSIVO™ (celiprolol) Details Genetic disorder | Phase 3 Data readout | |
ACER-801 (osanetant) Details Menopause, Hot flashes | Failed Discontinued |